Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
Recruiting
- Conditions
- Melanoma
- Interventions
- Drug: Single agent, adjuvant anti-PD1 therapy
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- John Kirkwood
- Target Recruit Count
- 30
- Registration Number
- NCT06599619
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
Phase 1
Active, not recruiting
- Conditions
- Unresectable Melanoma
- Interventions
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- John Kirkwood
- Target Recruit Count
- 13
- Registration Number
- NCT04688658
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
Phase 2
Active, not recruiting
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- John Kirkwood
- Target Recruit Count
- 42
- Registration Number
- NCT03743766
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma
- First Posted Date
- 2013-09-17
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- John Kirkwood
- Target Recruit Count
- 7
- Registration Number
- NCT01943422
- Locations
- 🇺🇸
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions
Early Phase 1
Completed
- Conditions
- Atypical NeviMelanoma
- Interventions
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- John Kirkwood
- Target Recruit Count
- 17
- Registration Number
- NCT01568996
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Dendritic Cells (DC) Vaccine for Metastatic Melanoma
Phase 2
Terminated
- Conditions
- Metastatic Melanoma
- Interventions
- Biological: Vaccination
- First Posted Date
- 2010-01-05
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- John Kirkwood
- Target Recruit Count
- 16
- Registration Number
- NCT01042366
- Locations
- 🇺🇸
Upmc Upci Hcc, Pittsburgh, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath